The Online Investor
OLI Premium
Contrarian Outlook
Stock Option Ideas
Preferred Stock Newsletter
ChartZero.com
ChartZero

Slideshow Secondary Stock Offerings

By The Online Investor Staff, updated Fri., Jun. 5, 5:31 PM

Slide #18. Intellia Therapeutics, Inc. Secondary Offering

Company: Intellia Therapeutics, Inc. (NASDAQ:NTLA)
Date announced: 6/1/2020
Shares Offered: 5,479,453
Date of Pricing: 6/2/2020
Price Per Share: $18.25
Secondary Offering Details: Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, announced today that it has commenced an underwritten public offering of $75 million of shares of its common stock. Intellia also intends to grant the underwriters a 30-day option to purchase up to an additional fifteen percent (15%) of the shares of common stock offered in the public offering. All of the shares in the proposed offering are to be sold by Intellia. -updated 6/2- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, announced today the pricing of an underwritten public offering of 5,479,453 shares of its common stock at a public offering price of $18.25 per share. Intellia also granted the underwriters a 30-day option to purchase up to an additional 821,917 shares of its common stock. The gross proceeds from the offering, before deducting underwriting discounts and commissions and estimated offering expenses, are expected to be $100 million, excluding any exercise of the underwriters' option to purchase additional shares. All of the shares in the offering are to be sold by Intellia.

Intellia Therapeutics is a genome editing company focused on developing therapeutics utilizing a biological tool known as Clustered, Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR associated 9 (Cas9). This is a technology for genome editing, the process of altering selected sequences of genomic deoxyribonucleic acid. Co. utilizes its CRISPR/Cas9 platform across two areas: in vivo applications, in which CRISPR/Cas9 is the therapy, delivered to target cells within the body; and ex vivo applications, in which CRISPR/Cas9 creates the therapy of engineered human cells.

NTLA SEC Filing Email Alerts Service

Open the NTLA Page at The Online Investor »

Company Name:  Intellia Therapeutics Inc
Website:  www.intelliatx.com
Sector:  Biotechnology
Number of ETFs Holding NTLA:  27
Total Market Value Held by ETFs:  $131.60M
Total Market Capitalization:  $1.15B
% of Market Cap. Held by ETFs:  11.47%
 

Open the NTLA Page at The Online Investor (in a new window) »

June 5, 2020    5:31 PM Eastern
Quotes delayed 20 minutes



Buy (3.00 out of 4)
38th percentile
(ranked lower than approx. 62% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite

Secondary Stock Offerings | www.TheOnlineInvestor.com | Copyright © 1998 - 2020, All Rights Reserved

Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes, powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.